Evommune (EVMN) closed at $7.84 on November 10, 2026, up 2.5% from the previous close, on volume of 815,541 shares (30-day average 937,212).
Data as of November 10, 2026.
10-Nov-2026
Evommune to Present at Upcoming Investor Conferences
Business Wire (Mon, 9-Nov 8:05 AM ET)
Business Wire (Thu, 5-Nov 6:30 AM ET)
Evommune Announces $30 Million Private Placement
Business Wire (Wed, 4-Nov 5:10 PM ET)
Business Wire (Wed, 4-Nov 5:02 PM ET)
Market Chameleon (Thu, 1-Oct 4:20 AM ET)
Business Wire (Thu, 1-Oct 8:00 AM ET)
Business Wire (Wed, 23-Sep 4:05 PM ET)
Business Wire (Tue, 8-Sep 5:43 PM ET)
Market Chameleon (Mon, 29-Jun 5:00 AM ET)
Market Chameleon (Tue, 10-Feb 5:28 AM ET)
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.
Evommune trades on the NYSE stock market under the symbol EVMN.
As of November 10, 2026, EVMN stock price climbed to $7.84 with 815,541 million shares trading.
EVMN has a beta of 0.41, meaning it tends to be less sensitive to market movements. EVMN has a correlation of 0.00 to the broad based SPY ETF.
EVMN has a market cap of $284.53 million. This is considered a Small Cap stock.
Last quarter Evommune reported $0 in Revenue and -$.89 earnings per share. This fell short of revenue expectation by $-1 million and missed earnings estimates by -$.22.
The top ETF exchange traded funds that EVMN belongs to (by Net Assets): VTI, IWM, VXF, FESM, IWO.
EVMN has underperformed the market in the last year with a return of -59.4%, while the SPY ETF gained +11.2%. In the last 3 month period, EVMN fell short of the market, returning -44.3%, while SPY returned -2.7%. However, in the most recent 2 weeks EVMN has outperformed the stock market by returning +51.9%, while SPY returned -2.6%.
EVMN support price is $7.12 and resistance is $8.19 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that EVMN shares will trade within this expected range on the day.
